THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen Inc., (NASDAQ: AMGN) announced it has received a summary of preliminary results from the Cochrane Collaboration’s independent meta-analysis of patient-level data from previously conducted, randomized, controlled, clinical studies evaluating erythropoiesis-stimulating agents (ESAs) in cancer patients. Amgen has submitted the executive summary to regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA).
